Juliet Hamdan
Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, 211-63, Jordan.

DOI:https://doi.org/10.5912/jcb2445


Abstract:

It could be more useful to see personalized medicine as representing a promissory economy that helps to both mobilize resources for research and, to some extent, dictate the purposes to which that research is directed, rather than attempting to separate hype from genuine promise. The research study determines that analysis market trends and business opportunities for measuring the research used SPSS software because the data based on primary also quantitative. A subset of medical biotechnology's broader promissory economy is personalized medicine. As a result, it consistently mixes up the pursuit of economic interests, particularly pharmaceutical ones, with the public good. As a result, research and development in personalized medicine frequently prioritizes the creation of costly new medicines over less profitable preventative measures or the more efficient application of established treatments. Overall research found that direct and significant link between them. Priorities for research must be rebalanced to support the pursuit of public benefit, even if it does not result in private profits. Public research funders and the scientists they support will therefore need to engage in prolonged introspection, self-criticism, and frequently self-denial.